HOME
ABOUT US
ADVERTISE
SUBSCRIBE
SITE MAP
HELP
CONTACT
WORK FOR US
Tuesday
7 September 2010
Make BTN my HomePage
HEALTH BIOTECH STORIES
[ 1163 Results - Showing Results 1 to 30 ]
HealthLinx breaches rule *UPDATED*
(Tuesday, 7 September 2010)
DIAGNOSTICS developer HealthLinx has negotiated a temporary halt to SpringTree Special Opportunities Fund’s monthly investment after a material calculation error led to a breach of listing rule.
Full Story...
Market Pulse: Gaining amid uncertainty
(Sunday, 5 September 2010)
AS Australia waited for the independents to back a team, the market gained 3.9% as Acuvax rocketed 80% during a capital raising while ImpediMed gained 9.9% on news of its device’s fourth managed care contract.
Full Story...
Pam-beating rat whisperer makes debut
(Tuesday, 31 August 2010)
DRUG discoverer Bionomics has found its anti-anxiety and anti-depressant compound BNC210 reduced anxiety in rats without sedating them, as diazepam did.
Full Story...
Bio People: CogState, IM Medical, Sigma and more
(Tuesday, 31 August 2010)
IM Medical chief executive Roman Najdecki will move on to greener pastures at the end of September after Mark Scott Radiology Group general manager and new IM director Sergio Del Vecchio took the reins as managing director yesterday.
Full Story...
Bio Briefs: Phosphagenics, IM Medical, RA
(Saturday, 28 August 2010)
TRANSDERMAL drug delivery developer Phosphagenics’s corporate adviser Southern Cross Equities has predicted a near-term payoff from an anti-cellulite cream based on a fat-basting drug that failed a Metabolic Pharmaceuticals testing.
Full Story...
Clinuvel seeks thriller re-pigmentation
(Friday, 27 August 2010)
LATE-stage drug developer Clinuvel Pharmaceuticals will evaluate a sixth indication for its orphan drug Scenesse in patients with vitiligo, a skin pigmentation disorder which reportedly affected the late Michael Jackson.
Full Story...
ImpediMed pulls another reimbursement win
(Thursday, 26 August 2010)
MEDICAL devices producer ImpediMed has signed its first managed care contract to provide L-Dex lymphoedema-detection technology for female breast cancer patients as a preferred provider to some 3.5 million members.
Full Story...
Bio People: ANU, W+ES, IMBCom and more
(Thursday, 26 August 2010)
THREE early career researchers have accepted L’Oreal for Women in Science fellowships worth $60,000 as they investigate stem cells and breast cancer relapse, carbon capturing and malaria drug alterations for chloroquine-resistant parasites.
Full Story...
Unilife pinged
(Thursday, 26 August 2010)
AS Unilife Corporation takes on new debt to fund plant construction, the US-based company has responded to a “please explain” from ASX Compliance which queried a 16.5% drop in share price.
Full Story...
Avexa's second date with destiny
(Thursday, 26 August 2010)
AS it called a meeting of shareholders to vote on what could be another “board spill”, Avexa’s board has labelled the extraordinary general meeting requested by largest investor Calzada as a “waste of time and cost”.
Full Story...
CogState-Quixote duo tackles concussed
(Thursday, 26 August 2010)
AS contract research organisation and neurological testing company CogState reports a 15% increase in annual profit to $1.6 million, it has officially launched the Axon Sports joint venture with a North American company that sold its last venture to Nike.
Full Story...
Capital Briefs: Phylogica, Select, Neurodiscovery and more
(Thursday, 26 August 2010)
PATERSONS Securities has fully underwritten drug-discovery company Phylogica’s $2.4 million capital raising after a recent Eli Lilly contract win.
Full Story...
Bio Briefs: GTG, Starpharma, OMI and more
(Thursday, 26 August 2010)
GENETIC Technologies has settled two more disputes with US biotechnology companies.
Full Story...
We were rebuffed: Avexa
(Thursday, 26 August 2010)
AVEXA’S board has told shareholders its investor Calzada rebuffed the board’s efforts to “engage in good faith” with the shareholder.
Full Story...
Acrux reports maiden $47M profit
(Tuesday, 24 August 2010)
FOLLOWING its impressive commercialisation deal with large pharmaceutical company Eli Lilly, Acrux has reported its first-ever annual profit.
Full Story...
Bio Briefs: Prana, Stirling, CBio and more
(Tuesday, 24 August 2010)
MID-stage treatment developer Prana Biotechnology has received a key patent in the US that includes protection for its lead asset PBT2, which has shown promise in Alzheimer’s and Huntington disease.
Full Story...
Capital Briefs: Phylogica, Cardia, Eastland and more
(Tuesday, 24 August 2010)
FOLLOWING its recent $US1.5-98 million ($A1.7-110.5 million) partnership deal with AstraZeneca, Phylogica has gone into a trading halt as it prepares to undertake a capital raising to deliver discovery services to large pharmaceutical companies.
Full Story...
ASX names and shames
(Tuesday, 24 August 2010)
THE Australian Securities Exchange has named seven biotechnology companies which have not yet paid their annual listing fees.
Full Story...
Immuron delivers tasty NASH
(Tuesday, 24 August 2010)
FOLLOWING a successful Phase 1/2 trial of its dairy-derived colostrum powder in patients with metabolic condition fatty liver disease, immunotherapy product developer Immuron must choose whether to tackle insulin resistance, high blood fats or both as it advances its platform to US Food and Drug Administration-compliant trials.
Full Story...
Market Pulse: Look to the sky
(Monday, 23 August 2010)
AS Virax lost $9.2 million from its market capitalisation on a failed clinical trial, the life sciences reflected a stale market, with less than a quarter gaining last week.
Full Story...
FDA knocks back GBH fantasy
(Sunday, 22 August 2010)
A US Food and Drug Administration advisory panel has recommended a close formulation to controversial “date rape” drug gamma-hydroxybutyrate not be approved for a chronic fatigue indication after hearing there was a risk of widespread abuse.
Full Story...
Bio Briefs: Cellmid, QRxPharma, Starpharma and more
(Friday, 20 August 2010)
A PRECLINICAL study of two Cellmid monoclonal antibodies has shown both decrease the severity of multiple sclerosis in an animal model.
Full Story...
Europe trials reconfirm Sirtex strength
(Thursday, 19 August 2010)
ONCOLOGY treatment company Sirtex Medical says two independent studies in Europe have established that targeted treatment with its microspheres is an effective option for those with inoperable liver cancer.
Full Story...
Mesoblast progresses US orphan trial
(Tuesday, 17 August 2010)
BIOLOGIC products developer Mesoblast says it is on track to start an already-funded Phase 3 study of its off-the-shelf stem cells after a formal meeting with the US Food and Drug Administration.
Full Story...
ASIC eyeballs bottom line
(Thursday, 12 August 2010)
FOLLOWING the transfer of market supervision from the Australian Securities Exchange to the Australian Securities and Investments Commission earlier this month, ASX queries are rolling in, with Giaconda, AnaeCo and Benitec being the latest to respond to questions about their financials.
Full Story...
Hirshorn quits ITL board
(Thursday, 12 August 2010)
AS a shareholder push to roll the board of medical devices manufacturer ITL escalates, Cochlear founder and Four Hats Capital director Dr Michael Samuel Hirshorn has resigned.
Full Story...
Benitec funded, focused
(Thursday, 12 August 2010)
GENE silencing technology developer Benitec has told ASX Compliance it expects to pick up the pace after an upcoming United States Patent and Trademarks Office decision, funded by a two-year La Jolla Cove Investments funding facility worth $250,000 a month.
Full Story...
Bio People: Avexa, Cardia, Monash, and more
(Tuesday, 10 August 2010)
FORMER EpiTan (Clinuvel) chief executive and former FH Faulding & Co chief financial officer Iain Kirkwood has joined the Avexa board as a non-executive director.
Full Story...
Bio Briefs: Virax, Acrux, Tissue Therapies and more
(Tuesday, 10 August 2010)
BIO-pharmaceutical Virax has announced it expects results from a Phase 2a study of its HIV therapeutic vaccine VIR201 in the next fortnight.
Full Story...
Calzada to Avexa: Let's roll
(Tuesday, 10 August 2010)
AVEXA’s major shareholder Calzada has proposed a whole new board for the former HIV drug developer, suggesting three well-known biotech professional directors as independents and one Calzada representative.
Full Story...
Prev
Next
Company Search
Story Search
Advanced Search
UPCOMING
EVENTS
ABIC 2010 - Bridging Biology and Business
14th International Biotechnology Symposium & Exhibition 2010
BIO India Partnering Conference 2010
OZBIO2010
2010 Livestock Biotech Summit
BioPartnering Europe
View all events
TODAY'S NEWS
Broadvector prepares $24.5M bang
Bio People: Australia, Research Australia, KarmelSonix and more *UPDATED*
In Silico: Is the IPO window cracking open?
Capital Briefs: Select, Helicon, PharmaNet and more
Avexa-Calzada rebuffed or engaged?
Bio Briefs: Genesis, Epichem, Sirtex and more
HealthLinx breaches rule *UPDATED*
Pipeline Progress: QRxPharma, Tyrian, Prana and more
Market Pulse: Gaining amid uncertainty
Avexa bioadvisors on board
Disclaimer
|
© Copyright Aspermont Ltd
|
Privacy Policy
|
Terms and Conditions
